Kahlon P, Nabi S, Arshad A, Jabbar A, Haythem A
Turk J Haematol. 2016; 33(4):299-303.
PMID: 27093959
PMC: 5204184.
DOI: 10.4274/tjh.2015.0271.
Insam C, Mean M, Limacher A, Angelillo-Scherrer A, Aschwanden M, Banyai M
PLoS One. 2016; 11(2):e0148348.
PMID: 26906217
PMC: 4764360.
DOI: 10.1371/journal.pone.0148348.
Singer D, Hellkamp A, Yuan Z, Lokhnygina Y, Patel M, Piccini J
J Am Heart Assoc. 2015; 4(3):e001349.
PMID: 25736441
PMC: 4392426.
DOI: 10.1161/JAHA.114.001349.
Ageno W, Gallus A, Wittkowsky A, Crowther M, Hylek E, Palareti G
Chest. 2012; 141(2 Suppl):e44S-e88S.
PMID: 22315269
PMC: 3278051.
DOI: 10.1378/chest.11-2292.
Heit J, Lahr B, Petterson T, Bailey K, Ashrani A, Melton 3rd L
Blood. 2011; 118(18):4992-9.
PMID: 21890644
PMC: 3208304.
DOI: 10.1182/blood-2011-05-357343.
Reverse translational bioinformatics: a bioinformatics assay of age, gender and clinical biomarkers.
Fliss A, Ragolsky M, Rubin E
Summit Transl Bioinform. 2011; 2008:11-5.
PMID: 21347121
PMC: 3041524.
Why is warfarin underutilized in patients with atrial fibrillation?.
Flaker G, Schutz J
J Interv Card Electrophysiol. 2004; 10 Suppl 1:21-5.
PMID: 14739736
DOI: 10.1023/B:JICE.0000011342.26830.5f.
Anticoagulation therapy in children.
Ronghe M, Halsey C, Goulden N
Paediatr Drugs. 2003; 5(12):803-20.
PMID: 14658922
DOI: 10.2165/00148581-200305120-00004.
Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
Zivelin A, Rao L, RAPAPORT S
J Clin Invest. 1993; 92(5):2131-40.
PMID: 8227329
PMC: 288391.
DOI: 10.1172/JCI116814.
Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal.
Asherson R, Chan J, Harris E, Gharavi A, Hughes G
Ann Rheum Dis. 1985; 44(12):823-5.
PMID: 4083938
PMC: 1001791.
DOI: 10.1136/ard.44.12.823.
Protean manifestations of pylethrombosis. A review of thirty-four patients.
Witte C, Brewer M, Witte M, Pond G
Ann Surg. 1985; 202(2):191-202.
PMID: 3874612
PMC: 1250873.
DOI: 10.1097/00000658-198508000-00009.
Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
Holford N
Clin Pharmacokinet. 1986; 11(6):483-504.
PMID: 3542339
DOI: 10.2165/00003088-198611060-00005.
Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states.
Vigano DAngelo S, Comp P, Esmon C, DAngelo A
J Clin Invest. 1986; 77(2):416-25.
PMID: 3511097
PMC: 423361.
DOI: 10.1172/JCI112319.
Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing.
White R, Hong R, Venook A, Daschbach M, Murray W, Mungall D
J Gen Intern Med. 1987; 2(3):141-8.
PMID: 3295148
DOI: 10.1007/BF02596140.
Risk-benefit assessment of anticoagulant therapy.
Harrington R, Ansell J
Drug Saf. 1991; 6(1):54-69.
PMID: 2029354
DOI: 10.2165/00002018-199106010-00006.
Therapeutic target values in oral anticoagulation--justification of Dutch policy and a warning against the so-called moderate-intensity regimens.
Loeliger E
Ann Hematol. 1992; 64(2):60-5.
PMID: 1554796
DOI: 10.1007/BF01715346.
